Spanish CDMO 3P Biopharmaceuticals inks manufacturing deal with Intervacc

horse swimming in water
Spanish CDMO 3P Biopharmaceuticals inked a deal to produce the Strangvac equine vaccine to treat strangles. (Callipso/iStock/Getty Images Plus/Getty Images)

3P Biopharmaceuticals, a Spanish CDMO, has inked a deal with Sweden's Intervacc to produce the company’s Strangvac equine vaccine to treat strangles.

Financial terms of the agreement weren’t disclosed.

Strangles is caused by Streptococcus equi in horses and is highly contagious. It can cause severe infection leading to significant suffering and economic loss for the global equine industry, the company said. The vaccine is the first candidate in the pipeline of a new generation of such drugs that are being developed with recombinant proteins.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“This is an important milestone in the process to complete the registration of Strangvac® and especially considering that there is a huge need for a safe and efficacious vaccine against equine strangles as evidenced by all current reported outbreaks around the world,” Jan-Ingmar Flock, Intervacc’s chief executive, said in a statement.

The agreement covers transfer of the manufacturing technology, production of validation batches and long-term future commercial manufacturing.


Suggested Articles

Boehringer Ingelheim intends to make a significant investment in its three manufacturing sites in Mexico in the next three years.

Dendreon has signaled faith in its struggling prostate drug Provenge by signing a 10-year lease extension for its California manufacturing facility.

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.